

Day 2 Saturday, February 28, 2026

E : English E : Half-English (Presentations given by the Japanese presenters will be in Japanese, but the slides will be in English.)
LS : Luncheon Seminar SS : Sweets Seminar

		7:30	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00
Hall Building	Room 1			Opening Remarks	8:50~10:20 Symposium 1 Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with High Risk of Recurrence Hiroki Yamaguchi Toshihiro Miyamoto P.3	10:40~11:35 Awards ceremony	11:55~12:45 LS1 Shaping the Future of CML and GVHD (Novartis Pharma K.K.)	13:00~14:30 Symposium 2 CD19-CAR-T Cell Therapy Koji Kato Daisuke Tomizawa P.3	14:40~15:55 Panel Discussion Strategies for Selecting CAR-T Cell Therapy, Bispecific Antibodies, and Transplantation for Large B-Cell Lymphoma Koji Izutsu, Koji Kato P.4	16:10~17:00 SS1 Therapeutic Strategies Using Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma (Johnson & Johnson)						
	4F Hall C				8:50~9:30 Nursing Oral Session 1 Survivorship care for Post HSCT Kazuko Kawakatsu Reiko Fujimoto P.82	9:35~10:25 Nursing Educational Lecture 1 A Practical Workshop on Patient Education for Novice Hematopoietic Stem Cell Transplant Nurses P.4	Speakers: Ayako Mori Momoka Fukuzawa Shiho Watanabe Chair: Ayako Mori	11:55~12:45 LS2 Nudges in Nursing: Practical Strategies for Patient Behavior Change (SymBio Pharmaceuticals Limited)	13:00~14:20 Multidisciplinary Team Care 1 Communication Methods with Patients and Families Using Behavioral Economics Takahiro Fukuda P.5	14:30~15:50 Multidisciplinary Team Care 2 Nationwide Survey Aiming to Ease Dietary Restrictions for Transplant Patients Takahiro Fukuda Makoto Onizuka P.5	16:10~17:00 SS2 Advances in Long-Term Follow-Up Outpatient Care #LTU #QOL, #Team Approach #Continuity Care #Innovation (Meiji Seika Pharma Co., Ltd.)					
	Room 2				8:50~10:20 Sponsored Symposium 1 Latest Treatment Strategies for chronic GVHD: Knowledge from Pediatric and Adult Perspectives Yoshihiro Inamoto, Hideki Sano (Meiji Seika Pharma Co., Ltd.) P.6		11:55~12:45 LS3 Progress in CAR-T therapy - Treatment Lines, Early Intervention and Outcome Improvement - (Gilead Sciences K.K.)	13:00~14:30 Sponsored Symposium 2 Approaches to the Management of Fungal Infections in Hematology and Transplant Patients Session: Management of Fungal Infections in Hematopoietic Cell Transplantation Session: Management of Fungal Infections in Novel Hematology Therapies P.7	14:40~15:55 Symposium 3 How to Select the Optimal Donor for Hematopoietic Cell Transplantation Based on HLA? (JSTCT-JSHI Joint Symposium) Makoto Murata, Satoko Morishima P.8	16:10~17:00 SS3 Treatment Approaches for Relapsed and Refractory FL (CHUGAI PHARMACEUTICAL CO.,LTD.)						
	7F Hall B7 (1)				8:50~10:20 Symposium 4 'Transplant Optimization in the PTCy Era': Exploring Practical Strategies Through the Latest Evidence and Case Discussions Hirohisa Nakamae, Junichi Sugita P.8		11:55~12:45 LS4 Latest Insights and Clinical Applications of CAR-T Cell Therapy in Relapsed Refractory Large B-Cell Lymphoma (R/R LBCL) (Bristol Myers Squibb K.K.)	13:00~14:30 Symposium 5 Immune Evasion in Transplantation and Cell Therapy Naoki Hosen Ken-ichi Matsuoka P.9	Takehiko Mori, Toshihiro Miyamoto (ASAHI KASEI PHARMA CORPORATION)				18:20~20:00 Reception			
	Room 3				8:50~9:20 Educational Lecture 1 Speaker: Hideki Nakasone Chair: Yu Akahoshi P.9	9:25~9:55 Educational Lecture 2 Speaker: Keiji Okinaka Chair: Takakazu Kondo P.9	10:00~10:30 Educational Lecture 3 Speaker: Keiji Nagafuji Chair: Takayoshi Tachibana P.9	11:55~12:45 LS5 The positioning of IsavuTdi in NDMM ~ One year of clinical experience and Shared Decision Making ~ (Sanofi K.K.)	13:00~14:00 National Survey News	14:10~14:40 Educational Lecture 4 Speaker: Yoshinobu Kanda Chair: Kaiko Harada P.10	14:45~15:15 Educational Lecture 5 Speaker: Yoshinobu Kanda Chair: Koji Kawamura P.10	15:20~15:50 Educational Lecture 6 Speaker: Atsushi Otsuka Chair: Yoshitaka Inoue P.10	16:10~17:00 SS4 Current Status and challenges of Hematopoietic Stem Cell Transplantation (Kyowa Kirin Co.,Ltd.)			
	7F Hall B7 (2)				8:50~10:20 HCTC Workshop Overseas Donor Coordination Mika Kotaki Yasuo Mori P.11	10:30~11:30 HCTC Roundtable Let's ask what kind of countermeasures and responses HCTC has implemented for its challenges Mariko Kawaguchi Yusuke Yamazaki P.12	11:55~12:45 LS6 Managing infections in hematological malignancies with hypogammaglobulinemia (Takeda Pharmaceutical Company Limited)	13:00~14:15 Symposium 6 Changes in Transplantation Due to the Introduction of Genetic Testing Yasuhiro Nannya Motohiro Kato P.13	14:25~15:55 Symposium 7 Treatment Strategies for Adult T-Cell Leukemia /Lymphoma Kaoru Uchamaru, Shigeo Fuji P.13	16:10~17:00 SS5 Treatment strategy for r/r B-ALL (Pfizer Japan Inc.)						
	Room 4				8:50~10:20 JSTCT-KSBMT Joint Symposium HCT for lymphoma: Recent trends in CAR-T era Hyeon-Seok Eom, Takanori Teshima P.14		11:55~12:45 LS7 How to tailor the sequence of different treatments in CLL: potentials of zanubrutinib therapy for CLL (BeOne Medicines Japan)	13:00~14:12 Oral Session 1 Chronic GVHD 1 Tetsuya Nishida P.29	14:25~15:25 Oral Session 2 Chronic GVHD 2 Yoshihiro Inamoto P.30	16:10~17:00 SS6 Major Breakthroughs in the Treatment of FLT3-ITD Positive AML (DAIICHI SANKYO COMPANY, LIMITED.)						
	Room 5				9:00~10:12 Oral Session 3 CAR-T: Complications 1 Toshio Kitawaki P.31		11:55~12:45 LS8 Initiatives for Regional Healthcare Collaboration DX Utilizing the Team-Based Clinical Support Service "Dr360" (SCSK Corporation)	13:00~14:12 Oral Session 4 Apheresis Hideki Goto P.32	14:25~15:37 Oral Session 5 Infection: Viral 1 Masao Ogata P.33	16:10~17:00 SS7 Fungal infections associated with hematologic disorders ~Drug-Drug Interactions of Antifungal Agents~ (ASAHI KASEI PHARMA CORPORATION)						
	Room 6				9:00~10:12 Oral Session 6 CAR-T/ Bispecific Antibody Yasuyuki Arai P.34		11:55~12:45 LS9 The 10-Year Challenge of Carfilzomib in the Treatment of Multiple Myeloma (ONO PHARMACEUTICAL CO.,LTD.)	13:00~14:12 Oral Session 7 GVHD Prophylaxis 1 Hirohisa Nakamae P.35	14:25~15:37 Oral Session 8 Transplant Outcomes: AML Masamitsu Yanada P.37	16:10~17:00 SS8 Optimal Apheresis Management Through Multidisciplinary Care: Lessons Learned and Next Steps (Terumo BCT)						
	Room 7				9:00~10:12 Oral Session 9 Basic science, HLA Tatsuo Ichinohe P.39		11:55~12:45 LS10 The Current Landscape of Acute GVHD Management: Real-World Utilization of Bone Marrow-Derived MSCs (JCR Pharmaceuticals Co., Ltd.)	13:00~14:12 Oral Session 10 Transplant Outcomes: Prognostic Modeling Takaaki Konuma P.40	14:25~15:37 Oral Session 11 Supportive Care Akiyoshi Takami P.42	16:10~17:00 SS9 Adverse events and their management in busulfan/thiotepa-conditioned autologous stem cell transplantation (Sumitomo Pharma Co., Ltd.)						
	Room 8				9:00~10:12 Oral Session 12 Immunotherapy: Basic science Yoshiki Akatsuka P.43		11:55~12:45 LS11 Progress of AML therapy and novel issues. (Astellas Pharma Inc.)	13:00~14:12 Oral Session 13 Early Complications 1 Nobuharu Fujii P.44	14:25~15:25 Oral Session 14 English: Myeloma Kazuhiro Suzuki P.45	16:10~17:00 SS10 The Usefulness of Capsule Endoscopy in Post-Hematopoietic Stem Cell Transplant Enteritis (Covidien Japan Inc.)						
	Room 9				9:00~10:12 Oral Session 15 Transplant Outcomes: ATL Makoto Yoshimitsu P.47		11:55~12:45 LS12 ATL Treatment Update (Minophagen Pharmaceutical Co., Ltd.)	13:00~14:12 Oral Session 16 Infection: Others Hiroyuki Fujita P.48	14:25~15:37 Oral Session 17 Late Complications 1 Shohei Yamamoto P.49	16:10~17:00 SS11 (AbbVie GK)						
	Room 10				9:00~10:12 Oral Session 18 Acute GVHD Kazuhiro Ikegame P.50		11:55~12:45 LS13 Immune thrombocytopenia (KOSSEI PHARMACEUTICAL CO.,LTD.)	13:00~14:12 Oral Session 19 Infection: Viral 2 Katsuto Takenaka P.51	14:25~15:37 Oral Session 20 Infection: Bacterial, Fungal Kumi Oshima P.52	16:10~17:00 SS12 Current treatment strategy for PTCL (Takeda Pharmaceutical Company Limited)						
	Room 11				8:50~11:05 US Hands-On Seminar (Nippon Shinyaku Co.,Ltd.) P.15		11:55~12:45 LS14 The strategy of time-limited combination therapies in CLL (Johnson & Johnson)	13:00~14:00 Oral Session 21 Transplant Outcomes: Myeloma, Elderly Takashi Ikeda P.53	14:25~15:37 Oral Session 22 Recurrence: Treatment Atsushi Wake P.54	16:10~17:00 SS13 Current treatment strategies and choice of JAK inhibitors for myelofibrosis (GlaxoSmithKline K.K.)						
Glass Building	Poster			9:00~11:00 Poster mounting	11:00~17:15 Poster viewing											17:15~18:05 Poster Presentation P.84
	B2F Hall E1															
	Exhibition				10:00~18:05 Exhibition (Hall B5 Foyer)											
Hall Building	B2F Hall E1			9:00 ~ 17:30 Exhibition (Hall B5 Foyer)												
	5F Hall B5 Foyer															
Tokyo International Forum																

Poster Presentation		
P1	Conditioning, Donor Selection	Mizuki Watanabe
P2	Acute GVHD	Masashi Sawa
P3	Chronic GVHD 1	Tetsuya Eto
P4	CAR-T: Lymphoma	Yu Yagi
P5	Transplant Outcomes: ALL	Aya Nishida
P6	Transplant Outcomes: AML	Hisashi Yamamoto
P7	Transplant Outcomes: T-cell Lymphoma	Nobuaki Nakano
P8	Transplant Outcomes: Others	Naoki Kurita
P9	Early Complications: TMA, VOD	Hideo Yagi
P10	Late Complications 1	Nobuhiko Uoshima
P11	Infection: Bacterial	Keiji Okinaka
P12	Infection: Bacterial, Fungal	Shun-ichi Kimura
P13	HCTC	Mari Saigusa
P14	Rehabilitation 1	Takahiro Takekiyo
P15	Pharmacist	Toshihisa Nakashima
P16	English session E	Yu Akahoshi
Nursing Poster Presentation		
看P1	Collaboration among Multidisciplinary Teams and Institutions	Shingo Sunagawa
看P2	Nutrition and Oral Care	Kanako Shiba
看P3	Psychosocial and Decision-Making Support	Rie Tsuruta
看P4	Support for CAYA HSCT Patients	Kazuyo Yoshikawa
看P5	Patient Education and Support	Miho Suzuki